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THE VALIDITY OF SERUM TSH MEASUREMENTS BY IMMUNOASSAY 
W.Graham Wood, Jürgen Habermann, Ingo Marschner, and 
Peter C.Scriba 
M e d i z i n i s c h e K l i n i k Innenstadt der Universität, 
Ziemssenstrasse 1, D 8000 München 2, F.R.G. 
According to Roget 1s Thesaurus, v a l i d i t y can be found 
among the synonyma f o r s e c t i o n 49 4 - T r u t h . V a l i d i t y im-
p l i e s accuracy and p r e c i s e n e s s and l i k e w i s e a u t h e n t i c i t y . 
A u t h e n t i c i t y of TSH, as determined by RIA may be a f f e c -
ted by 
incomplete e l i m i n a t i o n of c r o s s - r e a c t i o n of the a n t i -
body w i t h e.g. LH, FSH, HCG and t h e i r s u b u n i t s , 
- non s p e c i f i c i n t e r f e r e n c e of antigen-antibody i n t e r -
a c t i o n e.g. endogenous a n t i b o d i e s a g a i n s t TSH, 
immunoactive m a t e r i a l l a c k i n g b i o a c t i v i t y and 
unexplained f a c t o r s . 
Some of the reasons f o r the l a c k o f a u t h e n t i c i t y w i l l 
be d e a l t w i t h by other c o n t r i b u t o r s d u r i n g t h i s meeting. 
The r e s t of t h i s paper w i l l be devoted to the e l u c i d a t i o n 
of accuracy and p r e c i s i o n of the radioimmunoassay f o r TSH. 
I t i s not p o s s i b l e to apply the methods of q u a l i t y 
c o n t r o l (Q.C.) i n c l i n i c a l chemistry (12), as there are 
no d e f i n i t i v e or Standard methods, except f o r a few Ste-
r o i d s . The Q.C. of Proteohormones i s important, i n view 
of the m u l t i p l i c i t y of a n t i s e r a and Standard m a t e r i a l at 
present i n use. I t has been demonstrated that the i n t r o -
d u c t i o n of reference p r e p a r a t i o n s alone has not l e d to a 
s t a n d a r d i s a t i o n of r e s u l t s from hormone immunoassays. The 
assay method i t s e l f p l a y s a much l a r g e r r o l e , e.g. the 
l e n g t h and type of i n c u b a t i o n , the bound/free Separation 
method, the antiserum, the way i n which the t r a c e r i s pre-
pared and the medium i n which the Standards are d i s s o l v e d 
(3). Because of these problems, a model of e x t e r n a l qua-
l i t y c o n t r o l survey (EQCS) was developed i n t h i s l a b o r a -
t o r y which allowed d i f f e r e n t i a t i o n between systematic and 
random e r r o r s . During the past s i x years t h i s concept has 
been enlarged and i s now known as the "Munich-Model f o r 
E x t e r n a l Q u a l i t y C o n t r o l of Hormone Assays" (4,7 , 8,1o). 
The "Munich-Model" f o r EQCS has f o u r strong p o i n t s : 
(1) T e s t i n g the accuracy a g a i n s t i n t e r n a t i o n a l r e f e r e n c e 
p r e p a r a t i o n s (Proteohormones) o r pure substances(T^, 
T^, c o r t i s o l ) . 
(2) P m p o i n t i n g probable systematic e r r o r s i n an assay 
System ( e f f e c t of i n c u b a t i o n , s t a n d a r d - s o l u t e , data-
p r o c e s s i n g ) . 
(3) A c r i t i c a l but c o n s t r u c t i v e a n a l y s i s of each p a r t i c i -
pant's data - together w i t h the s e t t i n g up of a "two-
way" contact i f needed. 
(4) An "automatic p o l i c i n g " of the k i t - m a r k e t without the 
need f o r l e g i s l a t i v e I n t e r v e n t i o n ! 
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The survey here d e s c r i b e d was c a r r i e d out i n 1977/78. 
EQCS - PLANNING AND EXECUTION 
(a) P r e p a r a t i o n 
Members of the German S o c i e t i e s f.Endocrinology and 
C l i n i c a l Chemistry, together w i t h k i t - p r o d u c e r s , State 
h o s p i t a l l a b o r a t o r i e s and p r i v a t e l a b o r a t o r i e s were i n -
v i t e d to p a r t i c i p a t e i n the survey. The p a r t i c i p a n t l i s t 
was f u l l y r e p r e s e n t a t i v e of a l l l a b o r a t o r y types i n the 
F e d e r a l Republic of Germany. Three q u a r t e r s of a l l l e t t e r s 
had been answered w i t h i n 4-5 weeks of d i s p a t c h S e r u m from 
c l i n i c a l l y r e l e v a n t p a t i e n t groups was c o l l e c t e d i n advan-
ce, together w i t h TSH-free serum ( a l l s e r a w i t h a t r a c e r -
b i n d i n g of 1oo-11o % i n the house a s s a y ) . A l l s e r a were 
f i l t e r e d through an asbestos f i l t e r under 5 Bar N2 to r e -
move f i b r i n c l o t s and b a c t e r i a . The c o l l e c t i o n p e r i o d was 
between 3 and 4 months. The p a r t i c i p a n t s were n o t i f i e d i n 
a second l e t t e r of the date of d i s p a t c h f o r the samples. 
Twenty samples of 1 ml were sent i n d r y - i c e by ex-
press post. Table 1 shows the composition of the EQCS-
s e r a . The main p o i n t here i s , t h a t the hidden Standard 
curve was of MRC 68/38 TSH i n human-TSH-free serum. Two 
s e r a contained TSH-antibodies, which probably arose from 
p a t i e n t s who had r e c e i v e d i n j e c t i o n s of bovine TSH at 
some p e r i o d i n the past. Two samples from another EQCS, 
run by the German S o c i e t y f o r C l i n i c a l Chemistry were 
k i n d l y donated by Dr.G.Röhle and P r o f e s s o r H.Breuer,Bonn, 
FRG. A d e t a i l e d q u e s t i o n a i r e was sent together w i t h the 
serum samples, which covered the l a b o r a t o r y method of the 
TSH assay and space f o r the raw data (counts and concen-
t r a t i o n s f o r the l a b o r a t o r y i n t e r n a l Standard curve and 
f o r the 2o EQCS s e r a ) . 
(b) Data P r o c e s s i n g , N o t i f i c a t i o n of Performance 
Return of r e s u l t s took p l a c e around 4 months a f t e r 
the data had been r e c e i v e d . Because of a l l the raw data 
r e t u r n e d (see above), i t was p o s s i b l e to s t a n d a r d i s e the 
data p r o c e s s i n g of the Standard curve (curve I) - u s i n g 
a s p l i n e f u n c t i o n (6,9). This allowed a comparison w i t h 
the laboratory-own data p r o c e s s i n g , as w e l l as the compa-
r i s o n between l a b o r a t o r y own Standards and the hidden 
Standard curve (curve I I ) u s i n g MRC 68/38 TSH i n human 
TSH-free serum. 
The data from each p a r t i c i p a n t was t r a n s f e r r e d to 
punch cards (27-32 per p a r t i c i p a n t ) and read i n t o a Com-
puter (Siemens 4o4/3). The Computer program scheme and 
data-flow diagram have already been p u b l i s h e d i n d e t a i l 
(1o). The r e s u l t s from each p a r t i c i p a n t were p r i n t e d on 
6 s i d e s of Computer paper and r e t u r n e d to the p a r t i c i p a n t 
w i t h a s e t of histograms f o r a l l 2o samples showing ano-
nymously the d i s t r i b u t i o n of the values measured by a l l 
p a r t i c i p a n t s . This was accompanied by an explanatory 
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TABLE 1. Composition of the 2o samples f o r the EQCS. 
Sample No. Content 
1 Hidden Standard curve - 1o yuU/ml TSH (MRC 68/38) 
i n human TSH-free serum 
2 Bonn-EQCS No.4 - sample B I I 
3 Po o l serum - i n t r a - a s s a y c o n t r o l 
4 P o o l serum - i n t r a - a s s a y c o n t r o l 
5 P o o l serum i n lower ränge c o n t a i n i n g n a t i v e 
a n t i b o d i e s 
6 Po o l serum i n upper ränge 
7 B y k - M a l l i n c k r o d t - T h y r o i d Normal C o n t r o l Serum 
8 Poo l serum i n mid-range c o n t a i n i n g n a t i v e a n t i -
bodies 
9 Hidden Standard curve - 5 yuU/ml TSH 
10 Hidden Standard curve - 2o /uU/ml TSH 
11 Hidden Standard curve - 0 / a l l / m l TSH 
12 Hidden Standard curve - 2,5 pü/ml TSH 
13 Hidden Standard curve - 1/25 /iU/ml TSH 
14 Bonn-EQCS No.4 - sample A I I 
15 Po o l serum - i n t r a - a s s a y c o n t r o l 
16 Hidden Standard curve - o,62 juU/ml TSH 
17 Po o l serum - i n t r a - a s s a y c o n t r o l 
18 B y k - M a l l i n c k r o d t - Thyroid Hyper C o n t r o l Serum 
19 Hidden Standard curve - 4o yuU/ml TSH 
20 Po o l serum a t upper l i m i t of Standard curve 
A l l Standards were d i s s o l v e d i n human TSH-free serum. 
Samples 3,4,15 and 17 were i d e n t i c a l . _^ 
l e t t e r and by a d e t a i l e d e v a l u a t i o n of h i s Performance. 
Füll d e t a i l s are giv e n elsewhere (1o). - The support 
of t h i s study by the BMFT i s acknowledged. 
RESULTS 
PERFORMANCE OF PARTICIPANTS AND METHODS 
From 82 ret u r n e d s e t s of data, 8 were only p a r t l y 
usable, the other 74 being s u b j e c t e d to Computer a n a l y s i s . 
In s p i t e of the f a c t t h a t the number of u n i v e r s i t y c l i n i c 
l a b o r a t o r i e s was the h i g h e s t (n=24), t h i s group d i d not 
c o n s t i t u t e the m a j o r i t y of l a b o r a t o r i e s as i n the f i r s t 
EQCS i n 1976 (8 ) . 
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The i n t r a - a s s a y c o e f f i c i e n t * of V a r i a t i o n (c.v.) f o r 
the samples 3,4,15 and 17 were b e t t e r than i n 1976 ( 8 ) , 
only 21 l a b o r a t o r i e s (28 %) having an i n t r a - a s s a y c.v. 
above 15 % f o r 4 samples of the i d e n t i c a l serum. The rän-
ge of c.v. was 1.22 - 59.5 % (mean 4.64/uU/ml). 
Eleven d i f f e r e n t k i t s together w i t h a v a r i e t y of 
"own methods" were used by the p a r t i c i p a n t s . Table 2 
shows the k i t s and the main assay d e t a i l s . 
TABLE 2. L i s t of k i t s with incubation times and Separation 
techniques (Stand 1978). 
Manufacturer Separation technique Incubation(h) 
Diagnostic Products Corporation 2. Ab + 4 %* PEG 2,25 or 5,5 
Corning 1 .Ab bound to glassbeads +2,o 
Byk-Mallinckrodt 2. Ab 36 
CIS (Isotopen Dienst West) 2.Ab bound to c e l l u l o s e +16-2o 
Beckman 2. Ab 6,o 
Henning 2. Ab 24 or 72 
Abbott 18 % PEG 21 
Kabi 2.Ab +96 
Behring 2.Ab solid-phase 36-48 
Schwarz-Mann (Becton-Dickinson) 2. Ab 5,25 
Phadebas (Pharmacia) 2.Ab coupled to dextrose 36-48 
Bio-Rad 2.Ab solid-phase 5,o 
These methods have no preineubation 
PEG = Polyethyleneglycol (Mr 6ooo) 
F i g u r e 1 was chosen to demonstrate some important p o i n t s 
found i n t h i s survey. I t shows the d i s t r i b u t i o n of values 
measured f o r a serum (no.12) c o n t a i n i n g 2.5 /aU/ml MRC 
68/38 i n human TSH-free serum: 
The accuracy of many methods i s not acceptable as 
seen by the mean value of 4.o2 + 1.86yuU/ml. 
The absolute values of TSH measured d i f f e r w i d e l y , 
although most k i t s c a l i b r a t e d t h e i r Standards a g a i n s t 
MRC 68/38. Obviously, u s i n g the same Standard i s not 
enough to guarantee c o r r e c t r e s u l t s . 
The Standard d e v i a t i o n of the measured mean r e p r e -
sents an i n t e r - l a b o r a t o r y c.v. of 46.3 %. This c.v. i s 
b e t t e r than i n 1976 (8), however i s not y e t s a t i s f a c t o r y . 
The f i g u r e shows i n d i r e c t l y , t h a t many k i t s are not 
able to measure 2 yuU/ml TSH, however, t h i s i s of impor-
tance f o r t h y r o i d f u n c t i o n t e s t s e.g. i n order to measure 
the subnormal i n c r e a s e of TSH a f t e r TRH S t i m u l a t i o n . 
Beyond t h i s , none of the methods (Tab.2) had an 
average c.v. under 25.5 % f o r the ränge 0 - 4 yuU/ml 
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2.5 pU/ml MRC 68/38 
S a m p l e 12 
Figure 1. A l l measured values f o r sample No.12. The mean 
value and the two Standard d e v i a t i o n ränge are 
shown. F u r t h e r e x p l a n a t i o n see t e x t . 
(ränge of c.v. = 25.5 - 55.7 %),which must be r a t e d as 
u n s a t i s f a c t o r y . No k i t has the robustness f o r the lower 
ränge as d e s i r e d by EKINS (1). 
METH0D0L0GICAL STRATEGY 
The t r a c e r b i n d i n g of the p a r t i c i p a n t 1 s own-method 
zero Standard was compared w i t h t h a t of serum no.11 s e t 
at 1oo %, to check the b i n d i n g e f f e c t due to the Standard 
matrix alone. Three p a r t i c i p a n t s had values above 11o %, 
whose assays c o u l d be r a t e d as too i n s e n s i t i v e . 39 p a r t i -
c i p a n t s (53 %) showed acceptable z e r o - b i n d i n g between 9o 
and 11o % and almost h a l f , namely 32 p a r t i c i p a n t s , had 
values under 9o % g i v i n g r i s e to a "high blank" e f f e c t , 
i . e . e l e v a t e d values i n the lower ränge of the Standard 
curve. These data c o r r o b e r a t e t h a t i n accordance w i t h 
e a r l i e r o b s e r v a t i o n s (3,8) only human TSH-free serum i s 
optimal as m a t r i x f o r the Standard curve. 
F i g u r e 1 c o n t a i n i n g a l l measured values f o r sample 
no.12 allows a f u r t h e r c o n c l u s i o n , t h a t only k i t A showed 
a symmetrical Gaussian d i s t r i b u t i o n of co n c e n t r a t i o n s 
around the expected value This k i t used a p r e i n c u b a t i o n , 
had Standards i n TSH-free human serum and a c l a s s i c a l 
double-antibody method of Separation of bound and f r e e 
antigen. K i t s w i t h a s h o r t i n c u b a t i o n time - under 6 h -
the so c a l l e d "same day assay" k i t s are shown as B and 
k i t s w i t h no p r e i n c u b a t i o n are shown as C. Both B and C 
k i t s are l e s s s e n s i t i v e and l e s s accurate than the A k i t , 
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confirming e a r l i e r objections (2) to very short assays 
( i n s u f f i c i e n t incubation time) and o v e r - s i m p l i f i c a t i o n 
(e.g. no cold pre-incubation). 
The method used f o r bound/free Separation plays a de-
c i s i v e r o l e i n cases where antibodies are present i n serun. 
The k i t using 18 % Polyethylene g l y c o l (PEG) showed b i n -
ding well over the zero Standard i n sera 5 and 8, i . e . 
"negative" TSH values. The double antibody methods can 
also give f a l s e r e s u l t s inasmuch as the native antibodies 
compete with the test-anti-TSH. The second antibody, how-
ever, only p r e c i p i t a t e s the antiserum r a i s e d to human TSH, 
leaving the native antibody-TSH-complexes i n So l u t i o n , 
thus g i v i n g r i s e to f a l s e r e s u l t s (Tab.3). The e a s i e s t 
way to detect a native antibody to TSH i n serum samples 
would be to measure the u n s p e c i f i c binding using PEG-pre-
c i p i t a t i o n a f t e r incubation of the serum with t r a c e r . 
TABLE 3. E f f e c t o f n a t i v e a n t i b o d i e s on TSH values (/aV/ml; 
mean + SD) . 
Sample No. Expected value a l l p a r t i c i p a n t s PEG 2.Ab(1) 2.Ab(2) 
5 ca. 5 AiU/ml 8.81 + 4.o9 0 5.o3+1.71 15.7+5.56 
8 ca. 1o AiU/ml 1o.6 + 7.o1 0 9.65+1.91 1o.2+1.29 
(1), (2) Two k i t s as examples. 
STEPS TOWARDS ACCURACY 
Table 4 shows the regression-data from 74 p a r t i c i -
pants from whom a computer-evaluation was p o s s i b l e . The 
values f o r the c o r r e l a t i o n - c o e f f i c i e n t (r) and the re-
gression l i n e y = a + bx are given.The comparison of own 
re s u l t s vs. curve I shows only the d i f f e r e n c e i n the data-
processing (own method vs. s p l i n e f u n c t i o n ) . Here around 
3/4 of a l l methods are comparable (r> o.99; -1.o < a < 
+1.o; 1.1 > b > o.9). The comparison of curve I and curve 
II shows the influence of the sum of a l l assay method de-
t a i l s . Deviations from r = 1.oo reveal random err o r s i n 
the System. In t h i s survey 78.4 % of a l l p a r t i c i p a n t s had 
an r-value of above o.99, showing a good c o r r e l a t i o n . De-
vi a t i o n s from a = 0, the i n t e r c e p t point on the x-axis, 
show a p a r a l l e l displacement of the Standard curve when 
r and b approach 1.oo. In t h i s survey 6 8.9 % of a l l par-
t i c i p a n t s had an acceptable a-value. Deviations of b 
from 1.oo r e f l e c t the steepness of the standard-curve 
(accuracy). The larger the deviations of b from 1.oo, the 
worse the su p e r i m p o s i b i l i t y of own and hidden Standard 
curves. Here only 27 % of a l l p a r t i c i p a n t s had acceptable 
b-values (o.9o - 1.1o).This r e f l e c t s the non-optimal Sta-
te of a f f a i r s i n the TSH-assay at the time of t h i s EQCSI 
One of the main achievements of t h i s type of survey 
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TABLE 4. Regression data: 
Own r e s u l t s vs curve I and 
curve I vs curve II 
Regression equation: y = a + bx 
Parameter and 
boundaries 









r > o.99 59 (79.7) 58 (78.4) 
o.95 - o.99 8 (1o.8) 14 (18.9) 
< o. 9o 7 ( 9.5) 2 ( 2.7) 
Range 0.62 - 1.o o.49 - 1 . 0 
a > 1 . 0 yuU/ml 7 ( 9.5) 8 (1o.8) 
- 1 . 0 to +1.o yuU/ml 53 (71 .6) 51 (68.9) 
<-1 . 0 fiü/ml 14 (18.9) 1 5 (2o.3) 
Range -3.41 - 7.15 -10.5 - 3.95 
b > 1 .1o 17 (23.0) 13 (17.6) 
o.9o - 1. 1o 53 (71.6) 2o (27.0) 
< 0 . 9o 4 ( 5.4) 41 (55.4) 
Range o.75 - 1.36 o.47 - 1 .43 
Ideal values: r = 1, a = 0, b = 1 . 
i s the p o s s i b i l i t y to s e l e c t "reference l a b o r a t o r i e s " on 
the basis of t h e i r Performance. Ten l a b o r a t o r i e s p a r t i c i -
pating i n t h i s study (own method, n=4; k i t A, n=6) had an 
i d e a l s u p e r i m p o s i b i l i t y of t h e i r own standard-curve with 
the hidden standard-curve. The data returned by the "re f e -
rence l a b o r a t o r i e s " f o r samples no. 7,18,14,2 (Tab.5) may 
be considered as "assigned values". These assigned values 
obviously have a higher degree of accuracy than the me-
dian, target or mean values c u r r e n t l y i n use. 
DISCUSSION 
Two organisations are authorised to carry out EQCS i n 
the FRG for c l i n i c a l chemistry parameters and to give out 
c e r t i f i c a t e s f o r the parameters which have been measured 
with acceptable accuracy (11). Both organisations, namely 
the German Society f o r C l i n i c a l Chemistry (DGKCh) and the 
I n s t i t u t e f o r Standardisation and Documentation i n the 
Medical Laboratory (INSTAND) also carry out EQCS f o r hor-
mones. For these, two l y o p h i l i s e d serum samples are sent 
to each p a r t i c i p a n t f o r a n a l y s i s of several components. 
These r e s u l t s are worked out (using d i f f e r e n t S t a t i s t i c a l 
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TABLE 5. Assigned values f o r 4 samples from 1o "Reference 
L a b o r a t o r i e s " compared with values from o t h e r EQCS. 
TSH l e v e l s i n juU/ml. 





a l l p a r t i c i -




r a t o r i e s " 
7 - +7.5+2.5 + +8.22+2.75 + +6.93+1.16 
18 - 16.1+4.o 14.9 +5.22 11.6 +1.72 
14 2.1 - 2.65+1 .53 2.13+0.88 
2 16.6 - 17.2 +3.9o 15.2 +1.94 
+ - values 
- values 
r e p r e s e n t mean 
rep r e s e n t mean 
+ 2 SD 
+ 1 SD 
approaches) and returned to the p a r t i c i p a n t . Advantages of 
such surveys are t h e i r ease to c a r r y out and the frequen-
cy at which they can be repeated. Disadvantages are the 
lack of reference methods, l e a d i n g i n t u r n to a l a c k of 
" t a r g e t - v a l u e s " . When, to take an extreme case, the majo-
r i t y of l a b o r a t o r i e s f i n d values f o r the a n a l y t e concen-
t r a t i o n which are too h i g h , those who estimate the analy-
te c o r r e c t l y have values l y i n g e i t h e r o u t s i d e the -2 SD 
value or under the 2 o - % i l e . 
The S i t u a t i o n on the Steroid sector i s t almost i d e a l , 
i n asmuch as a d e f i n i t i v e method (isotope d i l u t i o n mass 
spectrometry - IDMS) can be used to e s t a b l i s h t r u e v a l u e s . 
A more i n t e n s i v e V a r i a t i o n of t h i s type of EQCS i s run by 
the World Health O r g a n i s a t i o n Human Reproduction U n i t 
(WHOHRU), (5). Here, 2 samples from a l a r g e s e t of serum 
pools (15-2o sera) are d i s t r i b u t e d at regulär i n t e r v a l s 
over a p e r i o d of 2 or 3 year s , which allows f o r a c o n t i -
nuous p r e c i s i o n c o n t r o l of the p a r t i c i p a n t ' s assays. The 
c o l l e c t i o n and storage of the l a r g e amounts of serum 
needed i s the drawback of t h i s survey. 
The disadvantages of the "Munich-Model" of EQCS are 
evident f o r both p a r t i c i p a n t and Organizer, r e s u l t i n g i n 
the i n f r e q u e n t repeat f o r each hormone every 2-3 years. 
For a small group, the amount of work i s f a r too much to 
ca r r y out regulär EQCS of t h i s model,which can only be 
performed f o r one, a t the most two, parameters. The advan-
tage i s the d e t a i l e d a n a l y s i s of methodology l e a d i n g to 
d e t e c t i o n of e r r o r s and e s t a b l i s h i n g a two way contact 
between Organizer and p a r t i c i p a n t . Furthermore, t h i s type 
of EQCS survey can be used to s e l e c t r e ference l a b o r a t o -
r i e s on the b a s i s of o b j e c t i v e c r i t e r i a and to e s t a b l i s h 
assigned v a l u e s . 
A compromise would be to use both types of EQCS, 
where the Munich-Model se t the t a r g e t values i n 1o-2o se-
rum pools,which could then be used i n a WHOHRU-type long 
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term EQCS. Furthermore, the reference l a b o r a t o r i e s chosen 
from the Munich Model EQCS could work w i t h matched r e a -
gents i n order to s e t the t a r g e t values even more accura-
t e l y , these matched reagents being e i t h e r an o r g a n i s o r -
produced or commercially-produced k i t . 
The time taken i n s e t t i n g t a r g e t values f o r 6 hormo-
nes i n the serum pools must be estimated a t 18-24 months. 
In the eyes of the authors, such an undertaking i n the 
FRG i s only p o s s i b l e i n c o n j u n c t i o n w i t h the DGKCh and 
INSTAND, and e v e n t u a l l y together w i t h k i t producers. 
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